MA52258B1 - Compositions ophtalmiques contenant un prostamide libérant de l'oxyde nitrique - Google Patents

Compositions ophtalmiques contenant un prostamide libérant de l'oxyde nitrique

Info

Publication number
MA52258B1
MA52258B1 MA52258A MA52258A MA52258B1 MA 52258 B1 MA52258 B1 MA 52258B1 MA 52258 A MA52258 A MA 52258A MA 52258 A MA52258 A MA 52258A MA 52258 B1 MA52258 B1 MA 52258B1
Authority
MA
Morocco
Prior art keywords
prostamide
releasing
compositions containing
nitric oxide
ophthalmic compositions
Prior art date
Application number
MA52258A
Other languages
English (en)
French (fr)
Other versions
MA52258A (fr
Inventor
Frédéric Pilotaz
Alan L. Weiner
Marina Do
Julien SALDO
Original Assignee
Nicox S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox S.A. filed Critical Nicox S.A.
Publication of MA52258A publication Critical patent/MA52258A/fr
Publication of MA52258B1 publication Critical patent/MA52258B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA52258A 2018-07-12 2019-07-10 Compositions ophtalmiques contenant un prostamide libérant de l'oxyde nitrique MA52258B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18290082 2018-07-12
PCT/EP2019/068511 WO2020011845A1 (en) 2018-07-12 2019-07-10 Ophthalmic compositions containing a nitric oxide releasing prostamide
EP20172140.4A EP3718535B1 (en) 2018-07-12 2019-07-10 Ophthalmic compositions containing a nitric oxide releasing prostamide

Publications (2)

Publication Number Publication Date
MA52258A MA52258A (fr) 2021-02-17
MA52258B1 true MA52258B1 (fr) 2025-07-31

Family

ID=63012964

Family Applications (2)

Application Number Title Priority Date Filing Date
MA52258A MA52258B1 (fr) 2018-07-12 2019-07-10 Compositions ophtalmiques contenant un prostamide libérant de l'oxyde nitrique
MA48919A MA48919B1 (fr) 2018-07-12 2019-07-10 Compositions ophtalmiques contenant un prostamide libérant de l'oxyde nitrique

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA48919A MA48919B1 (fr) 2018-07-12 2019-07-10 Compositions ophtalmiques contenant un prostamide libérant de l'oxyde nitrique

Country Status (28)

Country Link
US (5) US10688073B2 (https=)
EP (2) EP3718535B1 (https=)
JP (4) JP6672512B2 (https=)
KR (1) KR102861273B1 (https=)
CN (2) CN111249228B (https=)
AR (1) AR115734A1 (https=)
AU (2) AU2019300203B2 (https=)
BR (1) BR112021000240A2 (https=)
CA (1) CA3105989A1 (https=)
CY (1) CY1123706T1 (https=)
DK (1) DK3593788T3 (https=)
ES (2) ES2847853T3 (https=)
HR (2) HRP20251098T1 (https=)
HU (2) HUE072927T2 (https=)
LT (1) LT3593788T (https=)
MA (2) MA52258B1 (https=)
MD (2) MD3593788T2 (https=)
MX (2) MX2021000411A (https=)
MY (1) MY205816A (https=)
PH (1) PH12020552112A1 (https=)
PL (2) PL3718535T3 (https=)
PT (1) PT3593788T (https=)
RS (2) RS61348B1 (https=)
SG (1) SG11202100064WA (https=)
SI (1) SI3593788T1 (https=)
SM (2) SMT202100034T1 (https=)
TW (1) TWI839364B (https=)
WO (1) WO2020011845A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019300203B2 (en) * 2018-07-12 2025-01-30 Nicox S.A. Ophthalmic compositions containing a nitric oxide releasing prostamide
EP4404936A1 (en) * 2021-09-20 2024-07-31 Nicox SA Nitric oxide releasing prostamide as neuroprotective agent
JP7665073B1 (ja) 2024-04-05 2025-04-18 ロート製薬株式会社 容器に収容してなる眼科用組成物
US20260053768A1 (en) * 2024-05-07 2026-02-26 Maher Hadaya Sustained Nitric Oxide Releasing Drug Delivery Systems

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
US9629852B2 (en) 2007-10-16 2017-04-25 Sun Pharma Advanced Research Company Ltd. Ophthalmic composition comprising a prostaglandin
AR076731A1 (es) 2008-05-09 2011-07-06 Pfizer Prostamidas donadoras de oxido nitrico, uso de los mismos y composiciones farmaceuticas
MX2011002688A (es) 2008-09-12 2011-04-12 Critical Pharmaceuticals Ltd Mejoramientos en la absorcion de agentes terapeuticos a traves de las membranas mucosas o la piel.
US20130267591A1 (en) * 2010-05-07 2013-10-10 Sun Pharma Advanced Research Company Limited Novel ophthalmic compositions
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
BR112013034051A2 (pt) * 2011-06-29 2019-09-24 Allergan Inc formulações de macrogol 15 hidroxiestearato
CA2841644A1 (en) 2011-08-02 2013-02-07 Cipla Limited Pharmaceutical composition comprising ebastine and fluticasone
CN105012231A (zh) * 2014-04-30 2015-11-04 四川科伦药物研究院有限公司 一种包含PGF2α衍生物的稳定性良好的眼用制剂及其制备方法
CN105380901B (zh) * 2015-11-18 2018-07-17 侯宇华 一种他氟前列素滴眼剂及其制备方法
AU2019300203B2 (en) * 2018-07-12 2025-01-30 Nicox S.A. Ophthalmic compositions containing a nitric oxide releasing prostamide

Also Published As

Publication number Publication date
US12178793B2 (en) 2024-12-31
DK3593788T3 (da) 2021-01-11
PH12020552112A1 (en) 2021-05-31
BR112021000240A2 (pt) 2021-04-06
RS61348B1 (sr) 2021-02-26
SMT202100034T1 (it) 2021-03-15
ES2847853T3 (es) 2021-08-04
CN111249228B (zh) 2022-05-03
JP2022116147A (ja) 2022-08-09
JP2020011955A (ja) 2020-01-23
SI3593788T1 (sl) 2021-03-31
AU2019300203B2 (en) 2025-01-30
EP3718535C0 (en) 2025-06-18
US11020368B2 (en) 2021-06-01
MX2023007091A (es) 2023-06-27
EP3593788B1 (en) 2020-10-28
AU2019300203A1 (en) 2021-03-04
US20200206176A1 (en) 2020-07-02
PL3718535T3 (pl) 2025-10-13
KR102861273B1 (ko) 2025-09-17
AR115734A1 (es) 2021-02-17
LT3593788T (lt) 2021-04-12
SG11202100064WA (en) 2021-02-25
MA48919B1 (fr) 2021-02-26
MA48919A (fr) 2020-01-15
MY205816A (en) 2024-11-14
JP2020105201A (ja) 2020-07-09
EP3593788A1 (en) 2020-01-15
SMT202500425T1 (it) 2026-01-12
MX2021000411A (es) 2021-03-25
US20200016108A1 (en) 2020-01-16
MD3593788T2 (ro) 2021-03-31
CY1123706T1 (el) 2022-05-27
CN110237031B (zh) 2022-02-11
KR20210032435A (ko) 2021-03-24
MA52258A (fr) 2021-02-17
PL3593788T3 (pl) 2021-05-31
PT3593788T (pt) 2021-01-21
HUE052747T2 (hu) 2021-05-28
TW202019401A (zh) 2020-06-01
RS67054B1 (sr) 2025-08-29
EP3718535A1 (en) 2020-10-07
HRP20210138T1 (hr) 2021-03-19
EP3718535B1 (en) 2025-06-18
CN110237031A (zh) 2019-09-17
CN111249228A (zh) 2020-06-09
ES3036636T3 (en) 2025-09-23
HUE072927T2 (hu) 2025-12-28
JP7397910B2 (ja) 2023-12-13
CA3105989A1 (en) 2020-01-16
TWI839364B (zh) 2024-04-21
US20210128458A1 (en) 2021-05-06
WO2020011845A1 (en) 2020-01-16
MD3718535T2 (ro) 2025-08-31
AU2025203019A1 (en) 2025-05-15
US12186295B2 (en) 2025-01-07
JP6672512B2 (ja) 2020-03-25
JP2024023498A (ja) 2024-02-21
HRP20251098T1 (hr) 2025-11-07
US10688073B2 (en) 2020-06-23
US20250073196A1 (en) 2025-03-06
US20210220316A1 (en) 2021-07-22
JP7080268B2 (ja) 2022-06-03

Similar Documents

Publication Publication Date Title
MA52258B1 (fr) Compositions ophtalmiques contenant un prostamide libérant de l'oxyde nitrique
JOP20220069A1 (ar) عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
PH12020550341A1 (en) Niraparib formulations
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
NZ748016A (en) Use of cannabidiolic acid in the treatment of autism spectrum disorder and associated disorders
RU2013124024A (ru) Фармацевтическая композиция, содержащая мометазона фуроат и азеластина гидрохлорид, назального введения
EA202090448A1 (ru) Дигидрооксадиазиноны
MA39018A1 (fr) (aza)pyridopyrazolopyrimidinones et indazolopyrimidinones utilisées comme inhibiteurs de la fibrinolyse
EA202091003A1 (ru) Новые производные пиразолопирролопиримидиндиона в качестве ингибиторов p2x3
MX2023013683A (es) Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
MX2020010552A (es) Derivados de bumetanida para el tratamiento de la hiperhidrosis.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
AR114262A1 (es) Proceso para la preparación de un análogo de prostaglandina donante de óxido nítrico
PH12022553548A1 (en) Viscosity reducing excipients and combinations thereof for highly concentrated protein formulations
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
PE20221255A1 (es) Compuestos de curcumina y aminoacidos basicos
AR124724A1 (es) Proceso para la preparación de un análogo de prostaglandina donante de óxido nítrico
TH2101000072A (th) องค์ประกอบที่ใช้เฉพาะที่กับตาซึ่งมีพรอสตาไมด์ที่ปลดปล่อยไนตริกออกไซด์
MX2020007908A (es) Derivados de aminoacidos que contienen un grupo disulfanilo como un inhibidor de endopeptidasa neutra (nep) y aminopeptidasa n (apn) para la prevencion y el tratamiento del dolor del nervio trigemino.
CA3261164A1 (en) INDUSTRIAL PROCESS FOR THE PREPARATION OF HEXANOIC ACID, 6-(NITROOXY)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ETHYLAMINO)-7-OXO-2-HEPTEN-1-YL]-3,5-DIHYDROXYCYCLOPENTYL]-1-(2-PHENYLETHYL)-2-PROPEN-1-YL ESTER AND HIGH PURITY PRODUCT
MX2019011558A (es) Nuevos compuestos sustituidos de n'-hidroxicarbamimidoil-1,2,5-oxa diazol como inhibidores de indolamina 2,3-dioxigenasa (ido).
PL419082A1 (pl) Ksantohumol do zastosowania w leczeniu lub zapobieganiu i profilaktyce chorób hemoroidalnych oraz kompozycja zawierająca ksantohumol